Pacira Biosciences Inc (PCRX) Return on Assets ROA from the third quarter of 2026 to third quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Pacira Biosciences inc   (NASDAQ: PCRX)


Pacira Biosciences Inc 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Pacira Biosciences Inc 's ROA in the third quarter of 2026?
Pacira Biosciences inc achieved a return on average assets (ROA) of 3.06 % in its third quarter of 2026, this is above PCRX's average return on assets of -5.83%.
Pacira Biosciences Inc assets over the 12 months ending in its third quarter of 2026 are valued at $1,234 million

ROA has improved compared to 1.17% in the second quarter of 2026, due to net income growth.

However, within the Healthcare sector 197 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 2467, from total ROA ranking in the second quarter of 2026 at 2783.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Total Assets Change -6.7 % -18.52 % -23.83 % -18.58 % -14.73 %
Y / Y Net Income Change 425.06 % - -39.4 % -89.79 % -
Net Income (TTM) in million 38 15 5 7 21
Return On Assets (TTM) 3.06 % 1.17 % 0.39 % 0.49 % 1.44 %
PCRX's Total Ranking # 2467 # 2783 # 2009 # 3222 # 3195
Total Assets (TTM) in million 1,211 1,253 1,209 1,265 1,298
Seq. Total Assets Change -3.35 % 3.64 % -4.46 % -2.52 % -15.59 %
Seq. Net Income Change 512.96 % 59.57 % 78.13 % -69.86 % -

PCRX's 5 Years Annual ROA >> Back to PCRX Management Effectiveness >> Compare PCRX ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 66
Sector # 198
Overall # 2114

Return On Assets Statistics
High Average Low
13.92 %
-5.83 %
-45.52 %
(Dec 31 2020)   (Jun 30 2013)





Financial Statements
Pacira Biosciences Inc 's Assets $ 1,211 million PCRX's Balance sheet
Pacira Biosciences Inc 's Income $ 29 million Quarterly PCRX's Income Statement
PCRX's Income by Division See PCRX's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change -18.58 % -12.07 % 4.99 % -18.91 % 56.67 %
Total Assets in million 1,265 1,554 1,767 1,683 2,075
Y / Y Net Income Change - - 163.72 % -62.1 % -71.15 %
Net Income in million 7 -100 42 16 42
Annual Return On Assets 0.56 % -6.41 % 2.37 % 0.95 % 2.02 %

PCRX's 5 Years Annual ROA >> Back to PCRX Management Effectiveness >> Compare PCRX ROA to its Competitors



Comment on PCRX's ROA in the fiscal year ending 2025
In the fiscal year 2025 ROA improved to 0.56 % compared to prior year, due to annual net income growth of % to $7.03 million, and due to decline of value in Pacira Biosciences Inc 's assets by -18.58 % to $1,264.92 million, compared to $1,264.92 a year before.


More Return On Assets Ratios
PCRX's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
PCRX's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for PCRX's Competitors
Subscribers only: Roa for Pacira Biosciences Inc 's Suppliers
Subscribers only: Return On Assets for PCRX's Customers

You may also want to know
PCRX's Roi PCRX's Inventory Turnover Ratio PCRX's Growth Rates PCRX's Dividend Comparisons
PCRX's Profitability Ratios PCRX's Asset Turnover Ratio PCRX's Dividend Growth
PCRX's Roe PCRX's Valuation Ratios PCRX's Financial Strength Ratios PCRX's Dividend Payout Ratio



Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector ROA
Penumbra Inc  8.13 %
Johnson and Johnson  8.06 %
Pacific Health Care Organization Inc  7.83 %
Boston Scientific Corporation  7.82 %
Ani Pharmaceuticals Inc  7.77 %
Stryker Corp  7.66 %
Abbvie Inc   7.48 %
Ensign Group Inc  7.00 %
Pediatrix Medical Group Inc   6.99 %
Quest Diagnostics Inc  6.96 %
Davita Inc   6.65 %
Brightspring Health Services Inc   6.60 %
Ge Healthcare Technologies Inc   5.85 %
Merit Medical Systems Inc  5.72 %
Incyte Corporation  5.48 %
Labcorp Holdings Inc   5.36 %
Sotera Health Company  5.26 %
Black Hawk Acquisition Corporation  5.19 %
Pacs Group Inc   4.87 %
Iqvia Holdings Inc   4.65 %
Teleflex Incorporated  4.54 %
Haemonetics Corporation  4.30 %
Henry Schein Inc   3.84 %
U S Physical Therapy Inc  3.47 %
Lifestance Health Group Inc   3.30 %
Conmed Corporation  3.18 %
Integer Holdings Corporation  3.04 %
Avantor Inc   2.89 %
Ligand Pharmaceuticals Incorporated  2.74 %
Innovage Holding Corp   2.04 %

Date modified: 2026-11-07T13:19:36+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.